Highly sensitive single tube B-lymphoblastic leukemia/lymphoma minimal/measurable residual disease test robust to surface antigen directed therapy.

Qi Gao,Ying Liu,Umut Aypar,Jeeyeon Baik,Dory Londono,Xiaotian Sun, Jingping Zhang,Yanming Zhang,Mikhail Roshal

Cytometry. Part B, Clinical cytometry（2023）

引用 2|浏览9

暂无评分

摘要

The assay allows for sensitive disease detection of B-ALL MRD independent of CD19 and CD22 expression and allows uniform analysis of samples regardless of anti-CD19 and CD22 therapy.

查看译文

关键词

B-ALL,flow cytometry,measurable residual disease,target therapy

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要